Curology vs Agency: compare the current prescription, price and treatment goal

The common word personalized makes two services sound more alike than their treatment plans may be. Start with the concern: active breakouts, persistent pigment, visible aging or a combination that needs a clinician's assessment. Then compare the proposed prescription. A company name and monthly figure cannot establish that two preparations are substitutes.

The current public offers

These are public offers checked on 13 September 2026. Existing-account terms, initial promotions, shipping and proposed treatments can change the payable amount. Monthly equivalents are arithmetic for comparison, not a statement about billing frequency. Do not add the whole Agency range to a budget unless those products are actually part of the proposed care plan.

Ask for the assigned formula

Curology's acne page describes a three-ingredient prescription; Agency's current Night Renew page gives a broader candidate menu that includes estriol and does not guarantee tretinoin. Neither menu is your label. Ask for the selected ingredients, strengths, base, mass and beyond-use date. If a formula changes, keep both the previous and current specifications so a later response can be discussed accurately.

The clinical plan can change the comparison

If clindamycin is included, ask about antibiotic duration and how benzoyl peroxide is handled. If a hydroquinone or steroid-containing treatment is proposed, ask when it will be reviewed or changed. These are different treatment questions. A service comparison that reduces all of them to one best brand loses the detail needed to make a useful choice.

What would make the decision reviewable

• ▸The concern and the reason each proposed ingredient fits it.
• ▸The next actual charge, shipment quantity and renewal interval.
• ▸The clinician's contact route and what follow-up costs.
• ▸A date for reviewing response, side effects and continued need.
• ▸A clear explanation of whether an approved manufactured option could meet the same need.

Both custom preparations and approved products can be part of a clinical discussion. FDA's compounding distinction means ingredient evidence should not be presented as premarket review of a specific finished compound. We have not conducted patient comparisons of these services, so our partial scores assess public disclosure rather than medical quality or likely results.